Results 211 to 213 of about 3,791 (213)

Erratum: Phase II Study of 177Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers.

Journal of Clinical Oncology
F. Lin, J. Rivero, Jorge A Carrasquillo, A. Jha, J. Zou, Inna Shamis, S. Talvacchio, B. Turkbey, Erich P. Huang, Joanna H. Shih, Joanna Klubo-Gwiezdzinska, E. Mena, L. Lindenberg, Yating Teng, Freddy E Escorcia, Clara C Chen, Peter Herscovitch, C. Millo, P. Choyke, Karel Pacak   +19 more
semanticscholar   +1 more source

Prediction of 1 cm dose-equivalent rate on the day after administration of 177Lu-DOTATATE from 111In-somatostatine receptor scintigraphy prior to treatment

Annals of Nuclear Medicine
Go Takai, Kohei Hanaoka, Keiji Nagano, Tsutomu Okada, M. Honda, Izumi Komoto   +5 more
semanticscholar   +1 more source

SSA therapies—177Lu-DOTATATE is a better one in NETTER-1

Nature Reviews Clinical Oncology, 2015
openaire   +1 more source